AMGEN INC (1AMGN.MI) Stock Fundamental Analysis
Europe - BIT:1AMGN - US0311621009 - Common Stock
251.95 EUR
+12.1 (+5.04%)
Taking everything into account, 1AMGN scores 5 out of 10 in our fundamental rating. 1AMGN was compared to 75 industry peers in the Biotechnology industry. 1AMGN has an excellent profitability rating, but there are concerns on its financial health. 1AMGN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year 1AMGN was profitable.
1AMGN had a positive operating cash flow in the past year.
In the past 5 years 1AMGN has always been profitable.
In the past 5 years 1AMGN always reported a positive cash flow from operatings.
1.2 Ratios
1AMGN has a Return On Assets of 6.64%. This is amongst the best in the industry. 1AMGN outperforms 84.72% of its industry peers.
1AMGN has a Return On Equity of 95.59%. This is amongst the best in the industry. 1AMGN outperforms 98.61% of its industry peers.
With an excellent Return On Invested Capital value of 11.30%, 1AMGN belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for 1AMGN is in line with the industry average of 13.78%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.64% | ||
| ROE | 95.59% | ||
| ROIC | 11.3% |
ROA(3y)7.14%
ROA(5y)8.52%
ROE(3y)118.78%
ROE(5y)104.3%
ROIC(3y)13.04%
ROIC(5y)14.18%
1.3 Margins
The Profit Margin of 1AMGN (17.39%) is better than 86.11% of its industry peers.
In the last couple of years the Profit Margin of 1AMGN has declined.
1AMGN has a better Operating Margin (25.22%) than 86.11% of its industry peers.
In the last couple of years the Operating Margin of 1AMGN has declined.
1AMGN's Gross Margin of 64.07% is fine compared to the rest of the industry. 1AMGN outperforms 61.11% of its industry peers.
1AMGN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.22% | ||
| PM (TTM) | 17.39% | ||
| GM | 64.07% |
OM growth 3Y-6.36%
OM growth 5Y-7.03%
PM growth 3Y-18.6%
PM growth 5Y-18.28%
GM growth 3Y-2.94%
GM growth 5Y-3.32%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 1AMGN is still creating some value.
The number of shares outstanding for 1AMGN has been increased compared to 1 year ago.
Compared to 5 years ago, 1AMGN has less shares outstanding
The debt/assets ratio for 1AMGN has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.45, we must say that 1AMGN is in the distress zone and has some risk of bankruptcy.
1AMGN has a Altman-Z score (1.45) which is comparable to the rest of the industry.
1AMGN has a debt to FCF ratio of 5.26. This is a neutral value as 1AMGN would need 5.26 years to pay back of all of its debts.
The Debt to FCF ratio of 1AMGN (5.26) is better than 80.56% of its industry peers.
1AMGN has a Debt/Equity ratio of 8.70. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of 1AMGN (8.70) is worse than 70.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 8.7 | ||
| Debt/FCF | 5.26 | ||
| Altman-Z | 1.45 |
ROIC/WACC0.91
WACC12.42%
2.3 Liquidity
1AMGN has a Current Ratio of 1.17. This is a normal value and indicates that 1AMGN is financially healthy and should not expect problems in meeting its short term obligations.
1AMGN has a worse Current ratio (1.17) than 68.06% of its industry peers.
1AMGN has a Quick Ratio of 1.17. This is a bad value and indicates that 1AMGN is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.88, 1AMGN is not doing good in the industry: 73.61% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.17 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
1AMGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.43%, which is quite good.
1AMGN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.97% yearly.
Looking at the last year, 1AMGN shows a quite strong growth in Revenue. The Revenue has grown by 15.56% in the last year.
Measured over the past years, 1AMGN shows a small growth in Revenue. The Revenue has been growing by 7.43% on average per year.
EPS 1Y (TTM)11.43%
EPS 3Y5.02%
EPS 5Y5.97%
EPS Q2Q%23.74%
Revenue 1Y (TTM)15.56%
Revenue growth 3Y8.76%
Revenue growth 5Y7.43%
Sales Q2Q%9.43%
3.2 Future
1AMGN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.13% yearly.
1AMGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.73% yearly.
EPS Next Y7.16%
EPS Next 2Y5.12%
EPS Next 3Y5.1%
EPS Next 5Y4.13%
Revenue Next Year6.35%
Revenue Next 2Y3.99%
Revenue Next 3Y3.82%
Revenue Next 5Y2.73%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 13.97, which indicates a correct valuation of 1AMGN.
91.67% of the companies in the same industry are more expensive than 1AMGN, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.41. 1AMGN is valued slightly cheaper when compared to this.
1AMGN is valuated correctly with a Price/Forward Earnings ratio of 13.24.
Based on the Price/Forward Earnings ratio, 1AMGN is valued cheaply inside the industry as 91.67% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of 1AMGN to the average of the S&P500 Index (22.88), we can say 1AMGN is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.97 | ||
| Fwd PE | 13.24 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1AMGN is valued cheaply inside the industry as 83.33% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of 1AMGN indicates a rather cheap valuation: 1AMGN is cheaper than 86.11% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.29 | ||
| EV/EBITDA | 14.42 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
1AMGN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.95
PEG (5Y)2.34
EPS Next 2Y5.12%
EPS Next 3Y5.1%
5. Dividend
5.1 Amount
1AMGN has a Yearly Dividend Yield of 3.20%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 17.12, 1AMGN pays a better dividend. On top of this 1AMGN pays more dividend than 94.44% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.38, 1AMGN pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.2% |
5.2 History
On average, the dividend of 1AMGN grows each year by 9.41%, which is quite nice.
Dividend Growth(5Y)9.41%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
82.64% of the earnings are spent on dividend by 1AMGN. This is not a sustainable payout ratio.
The dividend of 1AMGN is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP82.64%
EPS Next 2Y5.12%
EPS Next 3Y5.1%
BIT:1AMGN (6/2/2025, 7:00:00 PM)
251.95
+12.1 (+5.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners83.58%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap135.48B
Analysts72.82
Price Target280.17 (11.2%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.2% |
Yearly Dividend7.83
Dividend Growth(5Y)9.41%
DP82.64%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.11%
Min EPS beat(2)2.49%
Max EPS beat(2)11.73%
EPS beat(4)3
Avg EPS beat(4)4.63%
Min EPS beat(4)-2.66%
Max EPS beat(4)11.73%
EPS beat(8)7
Avg EPS beat(8)4.04%
EPS beat(12)10
Avg EPS beat(12)3.24%
EPS beat(16)14
Avg EPS beat(16)3.6%
Revenue beat(2)1
Avg Revenue beat(2)-0.25%
Min Revenue beat(2)-0.84%
Max Revenue beat(2)0.34%
Revenue beat(4)1
Avg Revenue beat(4)-0.99%
Min Revenue beat(4)-2.15%
Max Revenue beat(4)0.34%
Revenue beat(8)2
Avg Revenue beat(8)-0.88%
Revenue beat(12)2
Avg Revenue beat(12)-1.03%
Revenue beat(16)3
Avg Revenue beat(16)-1.02%
PT rev (1m)-5.1%
PT rev (3m)-8.51%
EPS NQ rev (1m)-1.97%
EPS NQ rev (3m)-2.2%
EPS NY rev (1m)0.78%
EPS NY rev (3m)0.92%
Revenue NQ rev (1m)-0.19%
Revenue NQ rev (3m)-0.47%
Revenue NY rev (1m)0.34%
Revenue NY rev (3m)2.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.97 | ||
| Fwd PE | 13.24 | ||
| P/S | 4.57 | ||
| P/FCF | 14.29 | ||
| P/OCF | 12.79 | ||
| P/B | 25.13 | ||
| P/tB | N/A | ||
| EV/EBITDA | 14.42 |
EPS(TTM)18.03
EY7.16%
EPS(NY)19.03
Fwd EY7.55%
FCF(TTM)17.63
FCFY7%
OCF(TTM)19.7
OCFY7.82%
SpS55.13
BVpS10.03
TBVpS-61.65
PEG (NY)1.95
PEG (5Y)2.34
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.64% | ||
| ROE | 95.59% | ||
| ROCE | 12.97% | ||
| ROIC | 11.3% | ||
| ROICexc | 13.03% | ||
| ROICexgc | 56.9% | ||
| OM | 25.22% | ||
| PM (TTM) | 17.39% | ||
| GM | 64.07% | ||
| FCFM | 31.98% |
ROA(3y)7.14%
ROA(5y)8.52%
ROE(3y)118.78%
ROE(5y)104.3%
ROIC(3y)13.04%
ROIC(5y)14.18%
ROICexc(3y)15.77%
ROICexc(5y)17.27%
ROICexgc(3y)75.76%
ROICexgc(5y)77.1%
ROCE(3y)14.97%
ROCE(5y)16.28%
ROICexcg growth 3Y3.26%
ROICexcg growth 5Y-18.2%
ROICexc growth 3Y-8.67%
ROICexc growth 5Y-7.85%
OM growth 3Y-6.36%
OM growth 5Y-7.03%
PM growth 3Y-18.6%
PM growth 5Y-18.28%
GM growth 3Y-2.94%
GM growth 5Y-3.32%
F-Score6
Asset Turnover0.38
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 8.7 | ||
| Debt/FCF | 5.26 | ||
| Debt/EBITDA | 3.81 | ||
| Cap/Depr | 22.89% | ||
| Cap/Sales | 3.74% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 85.93% | ||
| Profit Quality | 183.97% | ||
| Current Ratio | 1.17 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | 1.45 |
F-Score6
WACC12.42%
ROIC/WACC0.91
Cap/Depr(3y)24.77%
Cap/Depr(5y)23.42%
Cap/Sales(3y)3.59%
Cap/Sales(5y)3.31%
Profit Quality(3y)165.92%
Profit Quality(5y)155.23%
High Growth Momentum
Growth
EPS 1Y (TTM)11.43%
EPS 3Y5.02%
EPS 5Y5.97%
EPS Q2Q%23.74%
EPS Next Y7.16%
EPS Next 2Y5.12%
EPS Next 3Y5.1%
EPS Next 5Y4.13%
Revenue 1Y (TTM)15.56%
Revenue growth 3Y8.76%
Revenue growth 5Y7.43%
Sales Q2Q%9.43%
Revenue Next Year6.35%
Revenue Next 2Y3.99%
Revenue Next 3Y3.82%
Revenue Next 5Y2.73%
EBIT growth 1Y22.01%
EBIT growth 3Y1.84%
EBIT growth 5Y-0.13%
EBIT Next Year37.48%
EBIT Next 3Y10.41%
EBIT Next 5Y5.07%
FCF growth 1Y44.93%
FCF growth 3Y7.44%
FCF growth 5Y4.03%
OCF growth 1Y41.42%
OCF growth 3Y7.45%
OCF growth 5Y4.66%